Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yang-Xun Pan

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
International Journal of Surgery (London, England)|February 16, 2024
Change of indocyanine green clearance ability and liver function after transcatheter intra-arterial therapies and its impact on outcomes of resectable hepatocellular carcinoma: a retrospective cohort studyYi-Xiang Gan, Zi-Liang Yang, Yang-Xun Pan, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|November 4, 2019
Radiofrequency ablation versus laparoscopic hepatectomy for hepatocellular carcinoma: A real world single center studyYang-Xun Pan, Qian Long, Min-Jiang Yi, et al.
Frontiers in Oncology|November 16, 2020
Stereotactic Body Radiotherapy vs. Radiofrequency Ablation in the Treatment of Hepatocellular Carcinoma: A Meta-AnalysisYang-Xun Pan, Yi-Zhen Fu, Dan-Dan Hu, et al.
Cancer Communications (London, England)|July 2, 2020
Tescalcin is an unfavorable prognosis factor that regulats cell proliferation and survival in hepatocellular carcinoma patientsZhong-Guo Zhou, Jin-Bin Chen, Rong-Xin Zhang, et al.
Frontiers in Immunology|May 7, 2024
The pattern of tumor progression on first-line immune checkpoint inhibitor-based systemic therapy for Chinese advanced hepatocellular carcinoma -CLEAP 004 studyChao-Xu Yang, Yang-Xun Pan, Feng Ye, et al.
American Journal of Cancer Research|June 9, 2020
Preventive effect of celecoxib in sorafenib-related hand-foot syndrome in hepatocellular carcinoma patients, a single-center, open-label, randomized, controlled clinical phase III trialJian-Cong Chen, Jun-Cheng Wang, Yang-Xun Pan, et al.
Cancers|August 8, 2019
Stereotactic Body Radiotherapy as a Salvage Therapy after Incomplete Radiofrequency Ablation for Hepatocellular Carcinoma: A Retrospective Propensity Score Matching StudyYang-Xun Pan, Mian Xi, Yi-Zhen Fu, et al.
Cancer Communications (London, England)|October 12, 2019
A nomogram predicting the recurrence of hepatocellular carcinoma in patients after laparoscopic hepatectomyYang-Xun Pan, Jian-Cong Chen, Ai-Ping Fang, et al.
Surgery|March 29, 2020
Intention to control low central venous pressure reduced blood loss during laparoscopic hepatectomy: A double-blind randomized clinical trialYang-Xun Pan, Jun-Cheng Wang, Xiao-Yun Lu, et al.
Frontiers in Oncology|May 13, 2025
Efficacy and safety of combined targeted therapy and immunotherapy versus targeted monotherapy in older patients with uHCCYu Li, Jian-Hong Zhong, Xiao-Dong Zhu, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
International Journal of Surgery (London, England)|February 16, 2024
Change of indocyanine green clearance ability and liver function after transcatheter intra-arterial therapies and its impact on outcomes of resectable hepatocellular carcinoma: a retrospective cohort studyYi-Xiang Gan, Zi-Liang Yang, Yang-Xun Pan, et al.
European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology|November 4, 2019
Radiofrequency ablation versus laparoscopic hepatectomy for hepatocellular carcinoma: A real world single center studyYang-Xun Pan, Qian Long, Min-Jiang Yi, et al.
Frontiers in Oncology|November 16, 2020
Stereotactic Body Radiotherapy vs. Radiofrequency Ablation in the Treatment of Hepatocellular Carcinoma: A Meta-AnalysisYang-Xun Pan, Yi-Zhen Fu, Dan-Dan Hu, et al.
Cancer Communications (London, England)|July 2, 2020
Tescalcin is an unfavorable prognosis factor that regulats cell proliferation and survival in hepatocellular carcinoma patientsZhong-Guo Zhou, Jin-Bin Chen, Rong-Xin Zhang, et al.
Frontiers in Immunology|May 7, 2024
The pattern of tumor progression on first-line immune checkpoint inhibitor-based systemic therapy for Chinese advanced hepatocellular carcinoma -CLEAP 004 studyChao-Xu Yang, Yang-Xun Pan, Feng Ye, et al.
American Journal of Cancer Research|June 9, 2020
Preventive effect of celecoxib in sorafenib-related hand-foot syndrome in hepatocellular carcinoma patients, a single-center, open-label, randomized, controlled clinical phase III trialJian-Cong Chen, Jun-Cheng Wang, Yang-Xun Pan, et al.
Cancers|August 8, 2019
Stereotactic Body Radiotherapy as a Salvage Therapy after Incomplete Radiofrequency Ablation for Hepatocellular Carcinoma: A Retrospective Propensity Score Matching StudyYang-Xun Pan, Mian Xi, Yi-Zhen Fu, et al.
Cancer Communications (London, England)|October 12, 2019
A nomogram predicting the recurrence of hepatocellular carcinoma in patients after laparoscopic hepatectomyYang-Xun Pan, Jian-Cong Chen, Ai-Ping Fang, et al.
Surgery|March 29, 2020
Intention to control low central venous pressure reduced blood loss during laparoscopic hepatectomy: A double-blind randomized clinical trialYang-Xun Pan, Jun-Cheng Wang, Xiao-Yun Lu, et al.
Frontiers in Oncology|May 13, 2025
Efficacy and safety of combined targeted therapy and immunotherapy versus targeted monotherapy in older patients with uHCCYu Li, Jian-Hong Zhong, Xiao-Dong Zhu, et al.
Pageof 2